

TruSight™ Oncology Comprehensive (EU)

A CE-marked, IVD, kitted
solution for comprehensive
genomic profiling (CGP)

- Detect actionable biomarkers across > 28 solid tumor types using minimal patient biopsy
- Assess current and emerging biomarkers from clinical practice guidelines, drug labels, and clinical trials simultaneously
- Deliver an easy-to-read, clinically relevant report that can help inform therapy decisions in 4-5 days
- Become a precision medicine provider by offering CGP testing in your institution



Revolutionizing cancer diagnostics

Comprehensive genomic profiling (CGP) is changing the face of cancer diagnostics. As the number of actionable biomarkers, approved therapies, and investigational trials increases, single-biomarker tests and targeted hotspot panels are unable to keep pace, increasing the chances of missing critical information. Furthermore, these methods do not detect certain current or emerging immunotherapy response signatures such as tumor mutational burden (TMB). One option for meeting the challenges of an ever-increasing list of potential therapies and biomarkers is next-generation sequencing (NGS)-based CGP. In a single test, CGP provides a comprehensive view of a tumor’s genetics, capturing information on hundreds of biomarkers, and reports clinically actionable results that can lead to molecularly matched therapeutic regimens and better patient outcomes.¹⁻⁶

Offering a CGP test in house provides numerous benefits, including the ability to maintain control over the patient’s biopsy and data, further empowering you as a precision medicine provider and increasing your participation in patient care. That said, CGP can be a complex undertaking when implemented as a laboratory-developed test (LDT). TruSight Oncology Comprehensive (EU)

(TSO Comprehensive (EU)) facilitates this onerous task. As a validated, CE-marked, IVD, kitted solution, TSO Comprehensive (EU) provides a streamlined CGP workflow starting with DNA or RNA and ending with clinically actionable results. All reagents and variant calling pipelines are extensively validated by Illumina, minimizing the time and effort of verifying a new solution and simplifying the implementation process.

About TSO Comprehensive (EU)

TSO Comprehensive (EU) is the first commercially available, *in vitro* diagnostic (IVD), kitted CGP test containing both DNA and RNA content. The NGS-based solution simultaneously analyzes 517 cancer-associated genes with known clinical relevance in one integrated workflow (Figure 1, Tables 1-4). The test includes kitted reagents for library preparation and sequencing and automated software pipelines that identify variants, interpret results, and produce clinically actionable reports. Sequencing is performed on the CE-marked IVD NextSeq™ 550Dx System. Using this solution, labs can provide CGP testing that yields timely, reliable information regarding relevant biomarkers as noted in primary literature, guidelines, drug labels, and clinical trials in less time and using less biopsy sample than current iterative methods.

Fully automated sequencing and data analysis




Figure 1: TSO Comprehensive workflow—Batch up to seven patient samples and two control samples per run using TSO Comprehensive (EU). The library preparation and enrichment steps take 2 days. The fully automated workflow on the NextSeq 550Dx System sequences samples; performs base calling and QC, variant calling, and interpretation, and generates a clinical report. The entire workflow is complete in 4-5 days.

Table 1: TSO Comprehensive (EU) at a glance

Feature	Description ^a
Sequencing system	NextSeq 550Dx System
Patient sample throughput	up to 7 patient and 2 control (1 positive and 1 NTC) samples per sequencing run
Panel content	<ul style="list-style-type: none"> • 517 genes for small variants • 23 genes for fusions • 2 genes for splice variants (<i>MET</i>, <i>EGFR</i>) • 2 genes for amplifications (<i>ERBB2</i>, <i>MET</i>) • TMB and MSI
Variant types detected	<ul style="list-style-type: none"> • DNA variants: SNVs, MNVs, insertions, deletions, gene amplifications • RNA variants: fusions, splice variants • Complex genomic signatures: TMB and MSI
Panel size	1.94 Mb DNA, 358 kb RNA
DNA input requirement	40 ng genomic DNA
RNA input requirement	40 ng total RNA
FFPE input requirement	Recommended tissue volume $\geq 1 \text{ mm}^3$ tissue Minimum 20% tumor content (by area) required to detect somatic driver mutations, $\geq 30\%$ tumor content required to detect MSI-high
No. of biopsy slides	Minimum 5 recommended (10 μM sections, 20 mm^2 tissue area each)
Total assay time	4-5 days from nucleic acid to clinical report
Limit of detection	See Appendix
False positives by DNA variant type	Gene amplifications, 0% Small DNA variants, 0.0001% MSI, 0% TMB, N/A
False positives by RNA variant type	RNA fusions, 0% RNA splice variants, 0%

a. NTC, no template control; N/A, not applicable.

Comprehensive biomarker profiling

Single-gene tests and targeted hotspot panels are limited in the number of targets they analyze and the type of variants they can detect. CGP with TSO Comprehensive (EU) overcomes these content limitations and simultaneously analyzes 517 genes with known cancer associations across > 28 solid tumor types in a single assay (Tables 2-4). The test calls multiple DNA and RNA variant types, including single nucleotide variants (SNVs), multiple nucleotide variants (MNVs), insertion/deletions (indels), gene amplifications, fusions, and splice variants (Figure 2). In addition, the test detects emerging immunotherapy biomarkers (ie, TMB⁷ and microsatellite instability (MSI)⁸⁻¹⁰). Content provides significant coverage of key guidelines for multiple tumor types and genes linked to clinical trials (Figure 3, Table 5). The inclusive nature of TSO Comprehensive (EU) maximizes the chances of finding a positive biomarker.




Figure 2: Variant types and genomic signatures detected by TSO Comprehensive (EU)

Companion diagnostic indications

Illumina has established multiple partnerships with several pharma companies to develop a growing pipeline of companion diagnostic (CDx) indications. This information will help identify patients who are likely to respond to specific therapies. TSO Comprehensive (EU) is currently indicated as a CDx test to identify cancer patients with solid tumors who are positive for *NTRK1*, *NTRK2*, or *NTRK3* gene fusions for treatment with VITRAKVI® (larotrectinib) in accordance with the approved therapeutic labeling.¹¹⁻¹³ Additional CDx indications, currently under development, will be included once they receive the appropriate regulatory approvals (Table 6).

Table 2: DNA content included in TSO Comprehensive (EU)

ABL1	BRCA2	CTNNB1	EWSR1	GATA1	IDH2	MAP3K13	NOTCH3	PNRC1	RPS6KA4	STK40
ABL2	BRD4	CUL3	EZH2	GATA2	IFNGR1	MAP3K14	NOTCH4	POLD1	RPS6KB1	SUFU
ACVR1	BRIP1	CUX1	FAM123B	GATA3	IGF1	MAP3K4	NPM1	POLE	RPS6KB2	SUZ12
ACVR1B	BTG1	CXCR4	FAM175A	GATA4	IGF1R	MAPK1	NRAS	PPARG	RPTOR	SYK
AKT1	BTK	CYLD	FAM46C	GATA6	IGF2	MAPK3	NRG1	PPM1D	RUNX1	TAF1
AKT2	C11orf30	DAXX	FANCA	GEN1	IKBKE	MAX	NSD1	PPP2R1A	RUNX1T1	TBX3
AKT3	CALR	DCUN1D1	FANCC	GID4	IKZF1	MCL1	NTRK1	PPP2R2A	RYBP	TCEB1
ALK	CARD11	DDR2	FANCD2	GLI1	IL10	MDC1	NTRK2	PPP6C	SDHA	TCF3
ALOX12B	CASP8	DDX41	FANCE	GNA11	IL7R	MDM2	NTRK3	PRDM1	SDHAF2	TCF7L2
ANKRD11	CBFB	DHX15	FANCF	GNA13	INHA	MDM4	NUP93	PREX2	SDHB	TERC
ANKRD26	CBL	DICER1	FANCG	GNAQ	INHBA	MED12	NUTM1	PRKAR1A	SDHC	TERT
APC	CCND1	DIS3	FANCI	GNAS	INPP4A	MEF2B	PAK1	PRKCI	SDHD	TET1
AR	CCND2	DNAJB1	FANCL	GPR124	INPP4B	MEN1	PAK3	PRKDC	SETBP1	TET2
ARAF	CCND3	DNMT1	FAS	GPS2	INSR	MET	PAK7	PRSS8	SETD2	TFE3
ARFRP1	CCNE1	DNMT3A	FAT1	GREM1	IRF2	MGA	PALB2	PTCH1	SF3B1	TFRC
ARID1A	CD274	DNMT3B	FBXW7	GRIN2A	IRF4	MITF	PARK2	PTEN	SH2B3	TGFBR1
ARID1B	CD276	DOT1L	FGF1	GRM3	IRS1	MLH1	PARP1	PTPN11	SH2D1A	TGFBR2
ARID2	CD74	E2F3	FGF10	GSK3B	IRS2	MLL/KMT2A	PAX3	PTPRD	SHQ1	TMEM127
ARID5B	CD79A	EED	FGF14	H3F3A	JAK1	MLLT3	PAX5	PTPRS	SLIT2	TMPRSS2
ASXL1	CD79B	EGFL7	FGF19	H3F3B	JAK2	MPL	PAX7	PTPRT	SLX4	TNFAIP3
ASXL2	CDC73	EGFR	FGF2	H3F3C	JAK3	MRE11A	PAX8	QKI	SMAD2	TNFRSF14
ATM	CDH1	EIF1AX	FGF23	HGF	JUN	MSH2	PBRM1	RAB35	SMAD3	TOP1
ATR	CDK12	EIF4A2	FGF3	HIST1H1C	KAT6A	MSH3	PDCD1	RAC1	SMAD4	TOP2A
ATRX	CDK4	EIF4E	FGF4	HIST1H2BD	KDM5A	MSH6	PDCD1LG2	RAD21	SMARCA4	TP53
AURKA	CDK6	EML4	FGF5	HIST1H3A	KDM5C	MST1	PDGFRA	RAD50	SMARCB1	TP63
AURKB	CDK8	EP300	FGF6	HIST1H3B	KDM6A	MST1R	PDGFRB	RAD51	SMARCD1	TRAF2
AXIN1	CDKN1A	EPCAM	FGF7	HIST1H3C	KDR	MTOR	PDK1	RAD51B	SMC1A	TRAF7
AXIN2	CDKN1B	EPHA3	FGF8	HIST1H3D	KEAP1	MUTYH	PDPK1	RAD51C	SMC3	TSC1
AXL	CDKN2A	EPHA5	FGF9	HIST1H3E	KEL	MYB	PGR	RAD51D	SMO	TSC2
B2M	CDKN2B	EPHA7	FGFR1	HIST1H3F	KIF5B	MYC	PHF6	RAD52	SNCAIP	TSHR
BAP1	CDKN2C	EPHB1	FGFR2	HIST1H3G	KIT	MYCL1	PHOX2B	RAD54L	SOCS1	U2AF1
BARD1	CEBPA	ERBB2	FGFR3	HIST1H3H	KLF4	MYCN	PIK3C2B	RAF1	SOX10	VEGFA
BBC3	CENPA	ERBB3	FGFR4	HIST1H3I	KLHL6	MYD88	PIK3C2G	RANBP2	SOX17	VHL
BCL10	CHD2	ERBB4	FH	HIST1H3J	KRAS	MYOD1	PIK3C3	RARA	SOX2	VTCN1
BCL2	CHD4	ERCC1	FLCN	HIST2H3A	LAMP1	NAB2	PIK3CA	RASA1	SOX9	WISP3
BCL2L1	CHEK1	ERCC2	FLI1	HIST2H3C	LATS1	NBN	PIK3CB	RB1	SPEN	WT1
BCL2L11	CHEK2	ERCC3	FLT1	HIST2H3D	LATS2	NCOA3	PIK3CD	RBM10	SPOP	XIAP
BCL2L2	CIC	ERCC4	FLT3	HIST3H3	LMO1	NCOR1	PIK3CG	RECQL4	SPTA1	XPO1
BCL6	CREBBP	ERCC5	FLT4	HNF1A	LRP1B	NEGR1	PIK3R1	REL	SRC	XRCC2
BCOR	CRKL	ERG	FOXA1	HNRNPK	LYN	NF1	PIK3R2	RET	SRSF2	YAP1
BCORL1	CRLF2	ERRF1	FOXL2	HOXB13	LZTR1	NF2	PIK3R3	RFWD2	STAG1	YES1
BCR	CSF1R	ESR1	FOXO1	HRAS	MAGI2	NFE2L2	PIM1	RHEB	STAG2	ZBTB2
BIRC3	CSF3R	ETS1	FOXP1	HSD3B1	MALT1	NFKBIA	PLCG2	RHOA	STAT3	ZBTB7A
BLM	CSNK1A1	ETV1	FRS2	HSP90AA1	MAP2K1	NKX2-1	PLK2	RICTOR	STAT4	ZFHX3
BMPRIA	CTCF	ETV4	FUBP1	ICOSLG	MAP2K2	NKX3-1	PMAIP1	RIT1	STAT5A	ZNF217
BRAF	CTLA4	ETV5	FYN	ID3	MAP2K4	NOTCH1	PMS1	RNF43	STAT5B	ZNF703
BRCA1	CTNNA1	ETV6	GABRA6	IDH1	MAP3K1	NOTCH2	PMS2	ROS1	STK11	ZRSR2

Content shaded in grey is analyzed for gene amplifications.












Pan-cancer: <i>BRAF, NTRK1, NTRK2, NTRK3, RET, MSI, TMB</i>													
Genes with biomarkers of clinical significance*											Genes with biomarkers of potential clinical significance†		
	Breast	<i>BRCA1</i>	<i>BRCA2</i>	<i>ERBB2</i>	<i>ESR1</i>	<i>PALB2</i>	<i>PIK3CA</i>					180	
	Colorectal	<i>ERBB2</i>	<i>KRAS</i>	<i>NRAS</i>								166	
	Bone	<i>EGFR</i>	<i>ERG</i>	<i>ETV1</i>	<i>ETV4</i>	<i>EWSR1</i>	<i>FEV</i>	<i>FLI1</i>	<i>FUS</i>	<i>H3F3A</i>	<i>HEY1</i>	<i>IDH1</i>	140
	Lung	<i>ALK</i>	<i>EGFR</i>	<i>ERBB2</i>	<i>KRAS</i>	<i>MET</i>	<i>NUTM1</i>	<i>ROS1</i>					223
	Melanoma	<i>KIT</i>	<i>NRAS</i>	<i>ROS1</i>									172
	Ovarian	<i>BRCA1</i>	<i>BRCA2</i>	<i>FOXL2</i>									149
	CNS‡	<i>APC</i>	<i>ATRX</i>	<i>CDKN2A</i>	<i>CDKN2B</i>	<i>EGFR</i>	<i>H3F3A</i>	<i>HIST1H3B</i>	<i>HIST1H3C</i>	<i>IDH1</i>	<i>IDH2</i>	<i>MYCN</i>	140
	Prostate	<i>AR</i>	<i>ATM</i>	<i>BARD1</i>	<i>BRCA1</i>	<i>BRCA2</i>	<i>BRIP1</i>	<i>CDK12</i>	<i>CHEK1</i>	<i>CHEK2</i>	<i>FANCL</i>	<i>FGFR2</i>	151
	Thyroid	<i>HRAS</i>	<i>KRAS</i>	<i>NRAS</i>	<i>TERT</i>								165
	Uterine & cervical	<i>BRCA2</i>	<i>EPC1</i>	<i>ERBB2</i>	<i>ESR1</i>	<i>FOXO1</i>	<i>GREB1</i>	<i>JAZF1</i>	<i>NCOA2</i>	<i>NCOA3</i>	<i>NUTM2A</i>	<i>NUTM2B</i>	138
	Other solid tumors	<i>ALK</i>	<i>APC</i>	<i>ARID1A</i>	<i>ASPSCR1</i>	<i>ATF1</i>	<i>ATIC</i>	<i>BAP1</i>	<i>BCOR</i>	<i>BRCA1</i>	<i>BRCA2</i>	<i>CAMTA1</i>	152
		<i>CARS</i>	<i>CENB3</i>	<i>CDK4</i>	<i>CDKN2A</i>	<i>CIC</i>	<i>CITED2</i>	<i>CLTC</i>	<i>COL1A1</i>	<i>COL6A3</i>	<i>CREB1</i>	<i>CREB3L1</i>	
		<i>CREB3L2</i>	<i>CSF1</i>	<i>CTNBN1</i>	<i>DDIT3</i>	<i>DDX3X</i>	<i>DNAJB1</i>	<i>DUX4</i>	<i>EED</i>	<i>EGFR</i>	<i>ERBB2</i>	<i>ERG</i>	
		<i>ETV1</i>	<i>ETV4</i>	<i>ETV6</i>	<i>EWSR1</i>	<i>FEV</i>	<i>FGFR2</i>	<i>FGFR3</i>	<i>FLI1</i>	<i>FOXL2</i>	<i>FOXO1</i>	<i>FOXO4</i>	
		<i>FUS</i>	<i>GLI1</i>	<i>HEY1</i>	<i>HGF</i>	<i>HMGA2</i>	<i>IDH1</i>	<i>KRAS</i>	<i>LEUTX</i>	<i>MAML3</i>	<i>MDM2</i>	<i>MYB</i>	
		<i>MYOD1</i>	<i>NAB2</i>	<i>NCOA2</i>	<i>NF1</i>	<i>NFATC2</i>	<i>NFIB</i>	<i>NR4A3</i>	<i>NRAS</i>	<i>NUTM1</i>	<i>NUTM2A</i>	<i>NUTM2B</i>	
		<i>PALB2</i>	<i>PATZ1</i>	<i>PAX3</i>	<i>PAX7</i>	<i>PDGFB</i>	<i>PDGFRA</i>	<i>PRKACA</i>	<i>PRKD1</i>	<i>RANBP2</i>	<i>ROS1</i>	<i>SDHA</i>	
		<i>SDHB</i>	<i>SDHC</i>	<i>SDHD</i>	<i>SMARCB1</i>	<i>SS18</i>	<i>SSX1</i>	<i>SSX2</i>	<i>SSX4</i>	<i>STAT6</i>	<i>SUZ12</i>	<i>TAF15</i>	
		<i>TCF12</i>	<i>TERT</i>	<i>TFE3</i>	<i>TFEB</i>	<i>TFG</i>	<i>TP53</i>	<i>TPM3</i>	<i>TPM4</i>	<i>TRAF7</i>	<i>TSPAN31</i>	<i>VGLL2</i>	
		<i>WT1</i>	<i>WWTR1</i>	<i>YAP1</i>	<i>YWHAE</i>	<i>ZC3H7B</i>							

Figure 3: Genes with key actionable biomarkers for multiple solid tumor types—Genes listed represent a subset of genes present in the TSO Comprehensive (EU) panel. Content analysis provided by Velsera based on IVD software Knowledge Base v8.5 (February 2023).

* Genes linked to current drug labels or guidelines.

† Based on evidence in scientific literature, presence in clinical trials, or linked to labels in other histologies.

‡ CNS, central nervous system.

Table 3: RNA content included in TSO Comprehensive (EU)

<i>ALK</i>	<i>BRAF</i>	<i>ERG</i>	<i>ETV4</i>	<i>FGFR3</i>	<i>NTRK1</i>	<i>PAX3</i>	<i>ROS1</i>
<i>AXL</i>	<i>EGFR</i>	<i>ESR1</i>	<i>FGFR1</i>	<i>KIF5B</i>	<i>NTRK2</i>	<i>RAF1</i>	<i>TMPRSS2</i>
<i>BCL2</i>	<i>EML4</i>	<i>ETV1</i>	<i>FGFR2</i>	<i>NRG1</i>	<i>NTRK3</i>	<i>RET</i>	

Genes listed are assessed for known and novel fusions.

Table 4: Splice variants included in TSO Comprehensive (EU)

<i>EGFR</i>	<i>MET</i>
-------------	------------

Table 5: TSO Comprehensive (EU) content coverage

49 Clinical practice guidelines
117 Drug labels
~680 European clinical trials
Analysis provided by Velsera based on the TSO Comprehensive (EU) software Knowledge Base. Current as of February 2023.

Table 6: CDx indications


CDx indication	Partner
solid tumors positive for <i>NTRK1</i> , <i>NTRK2</i> , or <i>NTRK3</i> gene fusions for treatment with VITRAKVI (larotrectinib)	Bayer ¹¹⁻¹³
Under development	
<i>RET</i>	Loxo@Lilly ¹¹
<i>EGFR</i>	Teligene ¹⁴
<i>HRD</i>	Myriad Genetics, Merck ^{15,16}
<i>TP53</i>	Kartos Therapeutics ¹⁷
MSI	Bristol Myers Squibb ¹⁵

CDx developments apply to the TSO Comprehensive (EU) portfolio. Availability of each CDx will vary by geography and is based upon variable timelines for therapy and test approvals by region.

More information, less sample, less time

TSO Comprehensive (EU) provides more information from less sample, in less total time compared to current iterative testing methods. For example, a potential journey for a

patient diagnosed with non-small cell lung carcinoma (NSCLC) following conventional testing methods could involve six different tests, requiring 29 sample slides and upwards of 42 days to obtain results regarding nine biomarkers, followed by analysis and interpretation time to develop a treatment plan.¹⁸⁻²³ In contrast, a CGP test using TSO Comprehensive (EU) typically requires five slides and up to five days to generate an actionable report with information on 500+ biomarkers and possible therapies and clinical trials (Figure 4).



* Includes complex genomic signatures
 † Does not include any slides required for H&E staining or other initial diagnosis
 ‡ Does not include newer biomarkers such as NTRK, TMB, MSI

Figure 4: Advantages of TSO Comprehensive (EU) compared to iterative testing—Example showing potential journeys for NSCLC patient. CGP with TSO Comprehensive (EU) provides substantially more coverage with less time and less sample compared to single-gene iterative testing.¹⁸⁻²³

One easy-to-read, actionable clinical report

TSO Comprehensive (EU) results, supported by an expertly curated Knowledge Base, are presented in a single, streamlined, actionable report. There's no need to search

multiple reports from tests performed over a period of time in an attempt to identify significant variants. The TSO Comprehensive (EU) report uses a tiering system to classify variants by clinical relevance level and can help inform therapy decisions according to clinical guidelines (Figure 5). The final report includes:

- Patient sample information—sample ID number, tumor type, sex, QC analysis, run ID, and Knowledge Base details
- Companion Diagnostic Results—detected variants or biomarkers that have a companion diagnostic intended use evaluated for the sample
- Genomic Findings with Evidence of Clinical Significance—detected variants that have evidence of clinical significance (therapeutic, prognostic, or diagnostic) based on information in FDA-approved drug labels, EMA-approved drug labels, ASCO Clinical Practice Guidelines, or ESMO Clinical Practice Guidelines for the patient’s tumor type, as specified by the Knowledge Base²⁴
- Genomic Findings with Potential Clinical Significance—detected variants that have potential clinical significance (therapeutic, prognostic or diagnostic) based on information in FDA-approved drug labels, EMA-approved drug labels, ASCO Clinical Practice Guidelines, or ESMO Clinical Practice Guidelines in another tumor type, match genomic and tumor type eligibility criteria for a clinical trial, or have evidence of potential clinical significance in the primary literature for the patient’s tumor type, as specified by the Knowledge Base and supporting rules engine²⁴

Validated solution

TSO Comprehensive (EU) is a validated, sample-to-answer CGP test that includes kitted reagents, a sequencing system (Table 7), and analysis software. The test was developed using a rigorous design control process

* ASCO, American Society of Clinical Oncology; EMA, European Medicines Agency; ESMO, European Society for Medical Oncology; FDA, Food and Drug Administration.

and validated across > 350 unique FFPE samples and > 55 different tumor types. Results were compared to orthogonal methods to ensure accurate, reproducible, and consistent data.

Using TSO Comprehensive (EU)

TSO Comprehensive (EU) provides a streamlined workflow that spans from sample input to final clinical report. After a 2-day library prep protocol, samples are loaded on to a flow cell and into the sequencing system where the remainder of the test is fully automated, including sequencing, variant calling, interpretation, and reporting. The entire test, from nucleic acid extraction to clinical report can be completed in as few as four days (Figure 1).

Table 7: Verification studies using TSO Comprehensive (EU)

Accuracy and clinical bridging studies for <i>NTRK1</i> , <i>NTRK2</i> , and <i>NTRK3</i> gene fusion detection	Library stability
Analytical accuracy	Limit of blank
Assay workflow guardbanding	Limit of detection
Cross contamination	Nucleic acid extraction kit evaluation
External controls evaluation	Real-time stability
Nucleic acid input titration guardbanding	Reproducibility
Interfering substances	Slide-mounted FFPE tissue stability
Kit in-use stability	Within-laboratory precision
Kit transport stability	

Prepare libraries

TSO Comprehensive (EU) can use DNA and RNA extracted simultaneously from the same sample as input material. If using DNA, sample preparation starts with shearing the genomic DNA (gDNA). If starting from RNA, the first step

1 Patient sample information

2 Companion diagnostic results

- Detected Companion Diagnostics variants/biomarkers and associated therapy indications

3 Genomic findings with evidence of clinical significance

- Variant name and genomic details

4 Genomic findings with potential clinical significance

- Includes TMB, MSI

5 Companion diagnostics QC

6 Companion diagnostics intended uses evaluated

- Includes tumor type, biomarkers, and eligible therapy

- 1 Patient sample information
- 2 Companion diagnostic results
 - Detected Companion Diagnostics variants/biomarkers and associated therapy indications
- 3 Genomic findings with evidence of clinical significance
 - Variant name and genomic details
- 4 Genomic findings with potential clinical significance
 - Includes TMB, MSI

- 5 Companion diagnostics QC
 - Positions with insufficient coverage for small variant detection
- 6 Companion diagnostics intended uses evaluated
 - Includes tumor type, biomarkers, and eligible therapy

7 Test information

- Genomics findings description
- Review of Knowledge Base
- Variant description
- Limitations of the test

8 Test information, continued

- Genes and variants tested

- 7 Test information
 - Genomics findings description
 - Review of Knowledge Base
 - Variant description
 - Limitations of the test

- 8 Test information, continued
 - Genes and variants tested

Figure 5: Clinical report for TSO Comprehensive—Reported includes companion diagnostics results and variants reported as clinically significant or potentially clinically significant based on an expertly curated knowledge base that includes clinical guidelines, drug labels, clinical trials, and peer-reviewed literature. The easy-to-read output is intended to increase confidence in treatment decisions.

is to reverse transcribe the sample into cDNA. Sheared gDNA and cDNA are converted simultaneously into sequence-ready libraries.

During library preparation, unique molecular identifiers (UMIs)²⁵ are added to the gDNA or cDNA fragments. These UMIs enable detection of variants at low variant allele frequency (VAF) while simultaneously suppressing errors, providing high specificity.

Enrich libraries to focus efforts

Library preparation is based on proven hybrid–capture chemistry using biotinylated probes and streptavidin-coated magnetic beads to purify selected targets from DNA- and RNA-based libraries. Regions of interest hybridize to the biotinylated probes, are magnetically pulled down, and then eluted to enrich the library pool. Hybridization-based enrichment is a useful strategy for analyzing specific genetic variants in a given sample and reliably sequencing exomes or large numbers of genes (eg, > 50 genes).

Hybrid–capture chemistry offers several advantages over amplicon sequencing, including yielding data with fewer artifacts and dropouts and the ability to accommodate larger panel enrichment. Additionally, hybrid–capture chemistry is fusion agnostic, enabling detection and characterization of known and novel fusions.

Sequence with diagnostic power

Prepared TSO Comprehensive (EU) libraries are sequenced on the NextSeq 550Dx System (Figure 6). The NextSeq 550Dx System is a CE-marked IVD instrument that enables clinical laboratories to develop and perform NGS-based IVD assays. The NextSeq 550Dx System features:

- A locked configuration with change control enabling laboratories to take advantage of current and future clinical testing options
- High-throughput capabilities to expand operations for larger, deeper studies or increase the number of patient

samples run

- Flexible analysis ranging from sequencing of small panels to WGS and NGS applications to microarray studies

With prefilled reagent cartridges, starting a run on a NextSeq 550Dx instrument is as easy as thaw, load, and go and takes roughly 30 minutes hands-on time. The intuitive interface allows users to perform various applications with minimal training or instrument set-up time. The NextSeq 550Dx instrument can deliver > 90 Gb of high-quality data with over 75% of bases sequenced with a quality score of Q30 or higher in less than two days.²⁶



Figure 6: The NextSeq 550Dx System—Developed under design control and manufactured following good manufacturing practice (GMP) guidelines, the NextSeq 550Dx System (in Dx mode) supports a fully automated TSO Comprehensive (EU) workflow from sequencing through final clinical report generation.

Patient batching throughput

Using TSO Comprehensive (EU) with the NextSeq 550Dx System, labs can batch up to seven patient samples† with two controls per sequencing run in 4-5 days.

Variant calling, interpretation, and reporting

All analysis for TSO Comprehensive (EU) is performed automatically on the NextSeq 550Dx System using the Local Run Manager TruSight Oncology Comprehensive (EU) Analysis Module. The on-instrument module facilitates run setup and performs secondary analysis of sequencing results, including demultiplexing, FASTQ file generation, alignment, and variant calling:

† Number of patient samples varies according to the number of controls run.

- Demultiplexing separates data from pooled libraries based on the unique sequence indexes that were added during the library preparation procedure
- FASTQ intermediate files contain the sequencing reads for each sample and quality scores, excluding reads from any clusters that did not pass filter
- Sequencing reads are aligned against a reference genome to identify a relationship between the sequences and assigned a score based on regions of similarity; aligned reads are written to files in Binary Alignment Map (BAM) format
- Separate algorithms for libraries generated from DNA and RNA samples are used to call small DNA variants, gene amplifications, TMB, and MSI for DNA samples, and fusions and splice variants for RNA samples with high specificity

The analysis software module generates multiple intermediate files, including sequencing metrics and Variant Call Format (VCF) files. VCF files contain information about variants found at specific positions in a reference genome. Sequencing metrics and individual output files are generated for each sample.

Tertiary analysis, also performed by the Local Run Manager TruSight Oncology Comprehensive Analysis Module, consists of TMB and MSI calculations, tumor profiling of variants into two levels of clinical significance, and report generation. The interpreted variant results, as well as the TMB and MSI biomarker results, are summarized in the TruSight Oncology Comprehensive results report. Clinicians can use the clinically actionable report to help inform therapy decisions according to clinical practice guidelines, drug labels, and clinical trials.

Clinically robust Knowledge Base

TSO Comprehensive (EU) Software is supported by a purpose-built over time, clinically derived rules engine and Knowledge Base to maximize report actionability. The rules engine and supported Knowledge Base, both provided by Velsera,²⁷ comprise extensive coverage of peer-reviewed publications, actionable variant information, and the most recent guidelines, drug labels, and clinical trials (Table 8, Figure 7). The TSO Comprehensive (EU) Software uses this

rich content to determine classifications of the detected genetic variants.




Figure 7: Knowledge Base creation—The TSO Comprehensive (EU) Tumor Profiling software is built on a foundation of extensively reviewed rules. Source rules, derived from clinical practice guidelines, drug labels, and primary literature, identify and classify actionable variants. Data from clinical trials and biological annotation databases are independent, standalone sources in the Knowledge Base.

Expertly curated content and rules engine

To deliver accurate interpretations of detected variants, the Knowledge Base relies on a rules engine (both provided by Velsera) that links specific variants or biomarkers to assertions of clinical impact in various tumor types. These assertions are aggregated from various clinical sources, including clinical practice guidelines (eg, ASCO, ESMO), approved drug labels (FDA, EMA), clinical trial registries (clinicaltrials.gov, EUCTR), primary literature describing clinical studies (PubMed), and biological

annotation databases (gnomAD, COSMIC)[‡] and can have therapeutic, prognostic, or diagnostic associations.

Supporting evidence for these assertions, known as source rules, are curated by a team of highly trained scientists and undergo extensive review following strict procedures. After this review, source rules are further examined in a Ruleset QC/QA process to ensure the integrity of the rule updates and that all required fields are properly populated. Source rules are then reviewed, ranked, and selected based on their relevance to a

Table 8: Knowledge Base facts as of March 2023^a

Topic	By the numbers
Drug labels	300+ labels reviewed 13K+ pages read
Guidelines	300+ oncology practice guidelines, each updated numerous times annually, reviewed 20K+ pages read
Published literature	100K+ papers reviewed 500K+ pages read
Clinical trials	81K+ trials reviewed
Device compliance	6.3K+ procedures, work instructions, forms, and records reviewed 65K+ pages read

a. Content is updated by Velsera on a monthly basis to incorporate the latest publications, biomarker discoveries, guidelines, drug labels, and clinical trials.²⁴

genomic finding to develop interpretation rules. Interpretation paragraphs are assembled based on the content associated with the appropriate rules, and the paragraphs include references to the source material as well.

Testing and quality assurance processes are in place to make sure that high-quality content is added and maintained in the Knowledge Base. In addition to the

[‡] ASCO, American Society of Clinical Oncology; COSMIC, Catalogue of Somatic Mutations In Cancer; EMA, European Medicines Agency; ESMO, European Society for Medical Oncology; EUCTR, European Clinical Trials Registry; FDA, Food and Drug Administration; gnomAD, Genome Aggregation Database.

reviews described above, clinical assertions are extracted using independent workflows by trained curators who are not part of the source rule or interpretation rule teams and the overall performance of the Tumor Profiling Software and Knowledge Base is assessed for concordance, specificity, and sensitivity. Accuracy of curated content is determined by comparing the classifications derived from the Knowledge Base metadata and the Tumor Profiling Software to classifications previously reported in the Velsera clinical data repository. The Knowledge Base undergoes periodic review by an expert panel of licensed and board-certified medical professionals, molecular pathologists, and medical oncologists.

An updated Knowledge Base is regularly made available²⁴ to account for new biomarkers; changes to guidelines, drug labels, and clinical trials; and newly published clinical research studies. IVD test providers can readily access the new releases, maximizing their ability to extract actionable information from this CGP test.

Reliable, high performance

The performance characteristics and reliability of TSO Comprehensive (EU) have been extensively tested to meet rigorous IVD requirements. Evaluations included a limit of blank study, limit of detection (LoD) studies for DNA and RNA variants, reproducibility, and analytical accuracy (Appendix).¹³ Qualitative studies across multiple operators, instruments, reagent lots, and days showed high concordance with minimal variance.¹³ For detailed information on the studies performed, refer to the Illumina TruSight Oncology Comprehensive (EU) Package Insert.¹³

Bring CGP into your lab

CGP maximizes the ability to find actionable biomarkers and inform therapy choices that have the potential to improve patient outcomes. CGP in your lab helps you:

- Be a precision medicine provider—Implement a state-of-the-art test and generate clinically actionable results in 4-5 days with reduced quantity not sufficient (QNS) rates and improved test success rates

- Be prepared for the future—Retain access to raw data files and reanalyze as new guidelines, drug labels, and clinical trials are introduced, potentially generating new actionable insights
- Be a trusted partner—Consult with oncologists on therapy decisions and participate in molecular tumor boards

Facilitated implementation

Implementing a CGP test can require significant time and effort. With the introduction of TSO Comprehensive (EU), Illumina has addressed some of the biggest challenges, streamlining the process. Starting with a highly validated, CE-marked, IVD, kitted solution:

- Reduces the time and expense of test implementation compared to a laboratory-developed test (LDT) (Figure 8)
- Expedites CGP moving from a “new” offering to a routine test
- Provides an *In Vitro* Diagnostic Directive (IVDD)-compliant test that is on the path to meeting *In Vitro* Diagnostic Regulation (IVDR) requirements, helping labs prepare to meet the stricter regulatory guidelines




Figure 8: Simpler, less burdensome test implementation—TSO Comprehensive (EU) is a CE-marked IVD test that requires only ISO 15189 performance verification, which is less burdensome than the validation required for a test developed in the laboratory. * Illustrative example. Not meant to provide a precise comparison of time and resources.

Comprehensive support

A comprehensive support program is available that will work with labs to expedite implementation and certification to ensure a smooth integration. The program provides:

- Onboarding plan to expedite test verification
- Laboratory training, including wet-lab instruction and run assessment from the expert Illumina Field Application Specialist team
- Verification protocol
- Training certification
- 24/5 technical support
- Ongoing support from the Illumina Medical Affairs team for medical inquiries

In addition, Illumina supplies IVD users with access to ready-to-use marketing and educational assets to share with their local health care providers and help them understand the value of CGP testing.

Access to reimbursement


CGP test coverage is an important consideration when bringing the capability in house. Reimbursement differs based on the country, clinical setting, and services provided. Currently, national or regional funding is available in some European countries (Figure 9). Illumina has established a dedicated Market Access team that is actively working with payers to further expand CGP test reimbursement across the globe.

Discuss available coverage options with your local Illumina Account Manager.

Figure 9: CGP test coverage options across Europe—Data current as of September 20, 2023.

Summary

The use of CGP testing is leading to improved patient outcomes. Implementing CGP testing in your lab is simplified with TSO Comprehensive (EU). This verified CGP test provides a streamlined workflow, validated reagents, and automated clinical software to take you from sample to clinical report in 4-5 days. Starting from DNA and RNA, use TSO Comprehensive (EU) to analyze multiple variant types in 500+ genes in a single test. Produce a clear, clinically relevant final report that accurately identifies actionable mutations that can be used to inform decisions regarding potential matched therapies or clinical trials, according to recognized sources, that might improve patient outcome.



Learn more

TruSight Oncology Comprehensive (EU), illumina.com/tsocomprehensive

Comprehensive genomic profiling (CGP), illumina.com/cgp

NextSeq 550Dx System, illumina.com/nextseq550dx

Ordering information

Product	Catalog no.
TruSight Oncology Comprehensive (EU) Kit	20063092
TruSight Oncology DNA Control	20065041
TruSight Oncology RNA Control	20065042
NextSeq 550Dx instrument	20005715
NextSeq 550Dx High-Output Reagent Kit v2.5 (300 cycles) ^a	20028871

a. Class I sequencing consumables have single lot shipment, kit lot testing, advance change notification, and a Certificate of Analysis available for each lot. Reagents are developed under design control principles, manufactured under current good manufacturing practices (cGMP), and verified to ensure specification compliance.

References

- Zehir A, Benayed R, Shah RH, et al. [Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.](#) *Nat Med.* 2017;23(6):703-713. doi:10.1038/nm.4333
- Soumerai TE, Donoghue MTA, Bandlamudi C, et al. [Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.](#) *Clin Cancer Res.* 2018;24(23):5939-5947. doi:10.1158/1078-0432.CCR-18-0412
- Gutierrez ME, Choi K, Lanman RB, et al. [Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.](#) *Clin Lung Cancer.* 2017;18(6):651-659. doi:10.1016/j.clcc.2017.04.004
- Singal G, Miller PG, Agarwala V, et al. [Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a](#)

Appendix

Limit of blank study

Low false positives for TSO Comprehensive (EU)

Parameter	Value
False positives for small DNA variants	0.0001%
False positives for gene amplifications	0%
False positives for MSI	0%
False positives for RNA fusions	0%
False positives for RNA splice variants	0%

False positives were assessed through a limit of blank study using FFPE normal or benign samples from adjacent tissue. False positives were not analyzed for TMB as there is no clinical cut-off value.

Limit of detection (LoD) studies

LoD—splice variants

Splice variant	LoD
<i>MET</i>	18.7
<i>EGFR</i>	24.8

FFPE samples from 17 tissue types containing variants were diluted to multiple test levels. Six observations were generated per level by two operators, each using a different reagent lot and instrument. LoD is defined as the lowest analyte value (eg, variant allele frequency or supporting reads) that can be detected consistently (95% detection limit or a type II error of 5%).

LoD—RNA fusions and splice variants

Fusion	LoD
<i>NCOA4-RET</i>	10
<i>TMPRSS2-ERG</i>	13.2
<i>KIF5B-RET</i>	14.5
<i>ACPP-ETV1</i>	17.2
<i>FGFR3-TACC3</i>	17.5
<i>EML4-ALK</i>	20.2
<i>FGFR1-GSR</i>	23.7
<i>EGFR-GALNT13</i>	24
<i>ESR1-CCDC170</i>	24.3
<i>FGFR2-SRPK2</i>	24.7
<i>HNRNPUL1-AXL</i>	26.3
<i>CD74-ROS1;GOPC</i>	28.2
<i>SPIDR-NRG1</i>	28.2
<i>RAF1-VGLL4</i>	28.5
<i>DHX8;ETV4-STAT3</i>	30.5
<i>MKRN1-BRAF</i>	31.2
<i>BCL2-IGHJ5</i>	44.2
<i>PAX3-FOXO1</i>	54.7

FFPE samples from 17 tissue types containing variants were diluted to multiple test levels. Six observations were generated per level by two operators, each using a different reagent lot and instrument. LoD is defined as the lowest analyte value (eg, variant allele frequency or supporting reads) that can be detected consistently (95% detection limit or a type II error of 5%).

LoD—small DNA variants and gene amplifications

Type (unit of measure for LoD)	Variant class/ Genomic content	No. of variants	Range
Small DNA variants (variant allele frequency)	SNVs	5	0.016–0.064
	MNVs	3	0.022–0.048
	Insertion (1-2 bp) near homopolymer repeats	2	0.086–0.104
	Insertion (1-2 bp) near dinucleotide repeats	2	0.038–0.051
	Insertion (3-5 bp)	2	0.030–0.056
	Insertion (> 5 bp and up to 25 bp)	3	0.034–0.215
	Deletion (1-2 bp) near homopolymer repeats	2	0.094–0.100
	Deletion (1-2 bp) near dinucleotide repeats	2	0.033–0.070
	Deletion (3-5 bp)	2	0.028–0.064
	Deletion (> 5 bp and up to 25 bp)	2	0.047–0.055
Gene amplifications (fold-change)	By gene (<i>ERBB2</i> , <i>MET</i>)	2	2.034–2.195

FFPE samples from 17 tissue types containing variants were diluted to multiple test levels. Six observations were generated per level by two operators, each using a different reagent lot and instrument. LoD is defined as the lowest analyte value (eg, variant allele frequency or supporting reads) that can be detected consistently (95% detection limit or a type II error of 5%).

Reproducibility for tumor profiling studies

Reproducibility for tumor profiling—Gene amplifications

Targeted gene	Mean fold-change ^a	PPC	95% CI ^b
<i>MET</i>	5.14	100.0%	92.6%, 100.0%
<i>ERBB2</i>	2.33	100.0%	92.4%, 100.0%

Reproducibility was tested across three sites (one internal, two external), two operators per site, three reagent lots, four testing days, and various sequencing runs per library using 41 FFPE tissue specimens and one cell line. PPC, percent positive call; CI, confidence interval

- a. Mean fold-change calculated from observed assay results.
- b. 95% two-sided CI calculated via the Wilson Score Method.

Reproducibility for tumor profiling—MSI

Panel member	Mean MSI score ^a	PPC	95% CI ^b
<i>TPSBD4</i>	60.5	100.0% (36/36)	90.4%, 100.0%
<i>TPSBD6</i>	55.7	100.0% (32/32)	89.3%, 100.0%
All members		100.0% (68/68)	94.7%, 100.0%

Reproducibility was tested across three sites (one internal, two external), two operators per site, three reagent lots, four testing days, and various sequencing runs per library using 41 FFPE tissue specimens and one cell line. PPC, percent positive call; CI, confidence interval

- a. Mean MSI score calculated from observed assay results.
- b. 95% two-sided CI calculated via the Wilson Score Method.

Reproducibility for tumor profiling—Small DNA variants

Gene	Variant type	Targeted variant (amino acid)	Mean VAF ^a	PPC	95% CI ^b
<i>APC</i>	Deletion	L1488fsTer19	0.181	100.0% (28/28)	87.9%, 100.0%
<i>APC</i>	Deletion	S1465WfsTer3	0.166	100.0% (40/40)	91.2%, 100.0%
<i>APC</i>	Insertion	T1556NfsTer3	0.227	100.0% (32/32)	89.3%, 100.0%
<i>APC</i>	Insertion	S1465fs*9	0.100	100.0% (48/48)	92.6%, 100.0%
<i>ARID1A</i>	Insertion	Q372fs*28	0.084	100.0% (4/4)	51.0%, 100.0%
<i>BRAF</i>	SNV	V600E	0.045	91.3% (42/46)	79.7%, 96.6%
<i>EGFR</i>	Deletion	E746_A750del	0.112	100.0% (46/46)	92.3%, 100.0%
<i>EGFR</i>	SNV	L858R	0.045	100.0% (38/38)	90.8%, 100.0%
<i>EP300</i>	Deletion	H2324fs*29	0.245	100.0% (44/44)	92.0%, 100.0%
<i>ERBB2</i>	Insertion	Y772_A775dup	0.075	100.0% (36/36)	90.4%, 100.0%
<i>IDH1</i>	SNV	R132H	0.155	100.0% (36/36)	90.4%, 100.0%
<i>KRAS</i>	MNV	G12I	0.111	100.0% (38/38)	90.8%, 100.0%
<i>NOTCH1</i>	Insertion	R1598fs*12	0.146	100.0% (48/48)	92.6%, 100.0%
<i>PTEN</i>	Deletion	T319fs*1	0.157	100.0% (44/44)	92.0%, 100.0%
<i>TP53</i>	Insertion	P152_P153dup	0.157	100.0% (2/2)	34.2%, 100.0%
<i>TP53</i>	Insertion	R333HfsTer5	0.154	100.0% (48/48)	92.6%, 100.0%

Reproducibility was tested across three sites (one internal, two external), two operators per site, three reagent lots, four testing days, and various sequencing runs per library using 41 FFPE tissue specimens and one cell line. VAF, variant allele frequency; PPC, percent positive call; CI, confidence interval

a. Mean VAF calculated from observed assay results.

b. 95% two-sided CI calculated via the Wilson Score Method.

Reproducibility for tumor profiling—RNA variants

Targeted variant	Variant type	Mean supporting reads	PPC	95% CI ^b
<i>ACPP-ETV1</i>	Fusion	44.7	100.0% (46/46)	92.3%, 100.0%
<i>BCL2-IGHJ5</i>	Fusion	124.9	100.0% (46/46)	92.3%, 100.0%
<i>CD74-ROS1;GOPC</i>	Fusion	56.6	100.0% (48/48)	92.6%, 100.0%
<i>DHX8;ETV4-STAT3</i>	Fusion	48.9	100.0% (46/46)	92.3%, 100.0%
<i>EGFR-GALNT13</i>	Fusion	49.8	100.0% (46/46)	92.3%, 100.0%
<i>EML4-ALK</i>	Fusion	49.3	100.0% (48/48)	92.6%, 100.0%
<i>ESR1-CCDC170</i>	Fusion	45.1	100.0% (46/46)	92.3%, 100.0%
<i>FGFR1-GSR</i>	Fusion	61.1	100.0% (46/46)	92.3%, 100.0%
<i>FGFR2-SRPK2</i>	Fusion	53.4	100.0% (48/48)	92.6%, 100.0%
<i>FGFR3-TACC3</i>	Fusion	53.5	100.0% (48/48)	92.6%, 100.0%
<i>HNRNPUL1-AXL</i>	Fusion	58.0	100.0% (48/48)	92.6%, 100.0%
<i>KIF5B-RET</i>	Fusion	11.6	91.7% (44/48)	80.4%, 96.7%
<i>MKRN1-BRAF</i>	Fusion	33.4	100.0% (48/48)	92.6%, 100.0%
<i>PAX3-FOXO1</i>	Fusion	70.1	100.0% (48/48)	92.6%, 100.0%
<i>RAF1-VGLL4</i>	Fusion	15.9	100.0% (46/46)	92.3%, 100.0%
<i>SPIDR-NRG1</i>	Fusion	51.5	100.0% (48/48)	92.6%, 100.0%
<i>TMPRSS2-ERG</i>	Fusion	43.5	97.9% (47/48)	89.1%, 99.6%
<i>EGFR VIII</i>	Splice variant	64.0	100.0% (46/46)	92.3%, 100.0%
<i>MET exon 14 skipping</i>	Splice variant	61.2	100.0% (48/48)	92.6%, 100.0%

Reproducibility was tested across three sites (one internal, two external), two operators per site, three reagent lots, four testing days, and various sequencing runs per library using 41 FFPE tissue specimens and one cell line. Percent negative call (PNC) was 100% for each targeted RNA variant, except for the *FGFR2-SRPK2* fusion (PNC = 99.60% (984/988); 95% CI: 98.96% to 99.84%). PPC, percent positive call; CI, confidence interval

a. Mean supporting reads calculated from observed assay results.

b. 95% two-sided CI calculated via the Wilson Score Method.

Analytical accuracy studies

Analytical accuracy—DNA variants and MSI


Variant type	Orthogonal method	PPA	NPA
Small DNA variants (somatic)	WES	85% (382/451) (95% CI: 81%-87%)	99.999% (70,000,481/70,000,907) (95% CI: 99.999%-99.999%)
Small DNA variants (germline)	WES	99.8% (33,163/33,224)(95% CI: 99.8%-99.9%)	99.999% (70,000,481/70,000,907) (95% CI: 99.999%-99.999%)
Gene amplifications	WES	92% (337/365) (95% CI: 89%, 95%)	98.3% (24,000/24,415) (95% CI: 98.1%, 98.5%)
MSI	MSI-PCR	93% (40/43) (95% CI: 81%, 98%)	99% (150/152) (95% CI: 95%, > 99%)

The ability of TSO Comprehensive (EU) to detect alterations in hundreds of FFPE samples was compared to the results achieved with the indicated reference method. At least 48% of the somatic variants detected by TSO Comprehensive (EU) were not detected by WES due to allele frequencies being below the WES threshold. WES data also showed evidence for the presence of additional variants detected by TSO Comprehensive (EU), but with low support from WES calls. This suggests that **these variants were missed in the tumor by WES** because of normal contamination. NPA, negative percent agreement; PPA, positive percent agreement; WES, whole-exome sequencing

Analytical accuracy—RNA variants

Variant type	Orthogonal method	PPA	NPA
Fusions	<ul style="list-style-type: none"> RNA whole-exome sequencing (RNGS1) Targeted NGS fusion panel (RNGS2) Droplet digital PCR (ddPCR) 	82% (63/77) (95% CI: 72%, 89%)	99.9% (13821/13839) (95% CI: 99.8%, 99.9%)
Splice variants	qPCR	57% (4/7) (95% CI: 25%, 84%)	100% (230/230) (95% CI: 98%, 100%)

The ability of TSO Comprehensive (EU) to detect alterations in hundreds of FFPE samples was compared to the results achieved with the indicated reference method. **TSO Comprehensive (EU) detected 41 fusions missed by orthogonal approaches.** LoD for RNGS1 was 4-8x that of TSO Comprehensive (EU), prompting use of additional methods with greater sensitivity, but less breadth of fusions. Confirmed additional 41 fusions detected by TSO Comprehensive using ddPCR. PPA and NPA scores for fusions represent a composite of the three orthogonal methods. Three samples were called positive for MET Exon 14 deletions by qPCR but not by TSO Comprehensive (EU) had an average Ct > 37, which is below the TSO Comprehensive (EU) LoD level. NPA, negative percent agreement; PPA, positive percent agreement; RNGS, RNA next-generation sequencing.



Analytical accuracy—TMB—The ability of TSO Comprehensive (EU) to detect TMB in > 100 FFPE samples was compared to the results achieved with whole-exome sequencing (WES). Results indicate a Pearson's correlation of 0.94.

- Clinicogenomic Database. *JAMA*. 2019;321(14):1391-1399. doi:10.1001/jama.2019.3241
5. Kato S, Kim KH, Lim HJ, et al. [Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy](#). *Nat Commun*. 2020;11:4965 (2020). doi.org/10.1038/s41467-020-18613-3
 6. Rozenblum AB, Ilouze M, Dudnik E, et al. [Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer](#). *J Thorac Oncol*. 2017;12(2):258-268. doi:10.1016/j.jtho.2016.10.021
 7. U.S. Food & Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. FDA website. [fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors](#). Released June 17, 2020. Accessed October 7, 2020.
 8. Tray N, Weber JS, Adams S. [Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application](#). *Cancer Immunol Res*. 2018;6(10):1122-1128. doi:10.1158/2326-6066.CIR-18-0214
 9. Samstein RM, Lee CH, Shoushtari AN, et al. [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](#). *Nat Genet*. 2019;51(2):202-206. doi.org/10.1038/s41588-018-0312-8
 10. U.S. Food & Drug Administration. FDA Approves First-Line Immunotherapy for Patients with MSI-H/bMMR Metastatic Colorectal Cancer. FDA website. [fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer](#). Released June 29, 2020. Accessed October 7, 2020.
 11. Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics. [businesswire.com/news/home/20180410005649/en/](#). Released April 10, 2018. Accessed February 22, 2021.
 12. As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi. [biopharmadive.com/news/as-lilly-deal-closes-bayer-secures-full-rights-to-loxos-vitrakvi/548584/](#). Released February 15, 2019. Accessed February 22, 2021.
 13. Illumina. [TruSight Oncology Comprehensive Package Insert](#). [support.illumina.com/sequencing/sequencing_kits/trusight-oncology-comprehensive.html](#). Accessed May 25, 2022.
 14. Illumina and Taolue Biopharmaceuticals Collaborate to Help Chinese Innovation Go Global. [illumina.com.cn/company/news-center/press-releases/2023/648d0d26-1f0a-4b65-b387-2c272761fbd711111.html](#). Released 2019. Accessed September 2024.
 15. Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling. [businesswire.com/news/home/20210111005930/en/Illumina-Announces-New-and-Expanded-Oncology-Partnerships-with-Bristol-Myers-Squibb-Kura-Oncology-Myriad-Genetics-and-Merck-to-Advance-Comprehensive-Genomic-Profiling](#). Released January 11, 2021. Accessed February 22, 2021.
 16. Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations. [prnewswire.com/news-releases/illumina-partners-with-merck-to-develop-and-commercialize-companion-diagnostic-and-research-tests-for-use-in-identifying-specific-cancer-mutations-301369838.html](#). Released September 7, 2021. Accessed October 14, 2021.
 17. Illumina. Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic. [illumina.com/company/news-center/press-releases/2021/12b6e4a6-3f52-407e-8200-8fa72712a980.html](#). Released 2021. Accessed February 9, 2024.
 18. Mayo Clinic Laboratories. EGFR - Specimen: EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor. Mayo Clinic Laboratories website. [mayocliniclabs.com/test-catalog/Specimen/35404](#). Accessed February 9, 2021.
 19. ARUP Laboratories. EGFR Mutation Detection by PyroSequencing. ARUP Laboratories website. [ltd.aruplab.com/Tests/Pub/2002440](#). Accessed February 9, 2021.
 20. Abbott. Vysis ALK Break Apart FISH Probe Kit. [molecular.abbott/sal/en-us/staticAssets/ALK-US-CE-Clinical-PI_R3_mw001_3060.pdf](#). Accessed February 9, 2021.
 21. NeoGenomics Laboratories. MET Exon 14 Deletion Analysis | NeoGenomics Laboratories. NeoGenomics Laboratories website. [neogenomics.com/test-menu/met-exon-14-deletion-analysis](#). Accessed February 9, 2021.
 22. Geisinger Medical Laboratories. Specimen collection and processing instructions for BRAF MUTATION ANALYSIS. Geisinger Medical Laboratories website. [geisingermedicallabs.com/catalog/details.cfm](#). Accessed February 9, 2021.
 23. Geisinger Medical Laboratories. Specimen collection and processing instructions for KRAS MUTATION ANALYSIS. Geisinger Medical Laboratories website. [geisingermedicallabs.com/catalog/details.cfm](#). Accessed February 9, 2021.
 24. Analysis provided courtesy of Velsera based on the TSO Comprehensive (EU) Knowledge Base. Current as of March 2023.
 25. Illumina. TruSight Oncology UMI Reagents. Illumina website. [https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/trusight-oncology-umi-reagents-datasheet-100000050425.pdf](#). Accessed February 9, 2021.

- 26. Illumina. NextSeq 550Dx Instrument. Available at <https://science-docs.illumina.com/documents/Instruments/nextseq-550dx-instrument-spec-sheet-1000000062591/nextseq-550dx-instrument-spec-sheet-1000000062591.pdf>. Accessed February 9, 2021.
- 27. Velsera. Genomic Knowledge Base for Clinical Next-Generation Knowledge. Velsera website. pieriandx.com/genomic-knowledge-base. Accessed October 2, 2023.

Intended use statement

TruSight Oncology Comprehensive (EU) is an *in vitro* diagnostic test that uses targeted next-generation sequencing to detect variants in 517 genes using nucleic acids extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from cancer patients with solid malignant neoplasms using the Illumina® NextSeq™ 550Dx instrument. The test can be used to detect single nucleotide variants, multinucleotide variants, insertions, deletions and gene amplifications from DNA, and gene fusions and splice variants from RNA. The test also reports a Tumor Mutational Burden (TMB) score and Microsatellite Instability (MSI) status.

The test is intended as a companion diagnostic to identify cancer patients for treatment with the targeted therapy listed in [Table 1](#), in accordance with the approved therapeutic product labeling. In addition, the test is intended to provide tumor profiling information for use by qualified healthcare professionals in accordance with professional guidelines and is not conclusive or prescriptive for labeled use of any specific therapeutic product.

Table 1: Companion diagnostics indication

Tumor type	Biomarkers	Targeted therapy
Solid tumors	<i>NTRK1, NTRK2, NTRK3</i> gene fusions	VITRAKVI (larotrectinib)



1.800.809.4566 toll-free (US) | +1.858.202.4566 tel
 techsupport@illumina.com | www.illumina.com

© 2024 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html.
 M-EMEA-00069 v6.0